These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Rifaximin and nonabsorbable disaccharides for hepatic encephalopathy. Guslandi M; Cella A Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):376. PubMed ID: 20134260 [No Abstract] [Full Text] [Related]
4. ACP Journal Club. Adding rifaximin to lactulose increased reversal and decreased mortality in hepatic encephalopathy. Kowdley KV; Burman BE Ann Intern Med; 2013 Oct; 159(8):JC8. PubMed ID: 24126669 [No Abstract] [Full Text] [Related]
5. How to dispel myths in the treatment of hepatic encephalopathy? Braillon A Nat Clin Pract Gastroenterol Hepatol; 2007 Oct; 4(10):E1; author reply E2. PubMed ID: 17909528 [No Abstract] [Full Text] [Related]
6. Rifaximin for episodic, overt hepatic encephalopathy: the data are catching up to clinical practice, but questions remain. Congly SE; Leise MD Am J Gastroenterol; 2014 Apr; 109(4):598. PubMed ID: 24698864 [No Abstract] [Full Text] [Related]
7. Response to Congly and Leise. Praveen S; Chander SB Am J Gastroenterol; 2014 Apr; 109(4):598-9. PubMed ID: 24698865 [No Abstract] [Full Text] [Related]
8. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147 [TBL] [Abstract][Full Text] [Related]
9. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713 [TBL] [Abstract][Full Text] [Related]
10. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837 [TBL] [Abstract][Full Text] [Related]
11. Disaccharides in the treatment of hepatic encephalopathy. Sharma P; Sharma BC Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517 [TBL] [Abstract][Full Text] [Related]
12. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Prasad S; Dhiman RK; Duseja A; Chawla YK; Sharma A; Agarwal R Hepatology; 2007 Mar; 45(3):549-59. PubMed ID: 17326150 [TBL] [Abstract][Full Text] [Related]
13. Lactulose for hepatic encephalopathy. Med Lett Drugs Ther; 1976 Jan; 18(1):3-4. PubMed ID: 1105127 [No Abstract] [Full Text] [Related]
14. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Huang E; Esrailian E; Spiegel BM Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657 [TBL] [Abstract][Full Text] [Related]
15. Should We Treat Minimal/Covert Hepatic Encephalopathy, and with What? Henderson PK; Herrera JL Clin Liver Dis; 2015 Aug; 19(3):487-95. PubMed ID: 26195203 [TBL] [Abstract][Full Text] [Related]
17. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Morgan MY Metab Brain Dis; 2016 Dec; 31(6):1361-1364. PubMed ID: 27638474 [TBL] [Abstract][Full Text] [Related]